AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.

US-based vaccine developer Moderna Therapeutics set its pricing range at $22 to $24 yesterday for an initial public offering that will offer exits to pharmaceutical firms Merck & Co, AstraZeneca and Alexion Pharmaceuticals. The company will issue 21.7 million shares and raise more than $521m if it floats at the top of the range. It…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.